Helena Aebersold, Fabienne Foster-Witassek, Stefanie Aeschbacher, Juerg H Beer, Eva Blozik, Manuel Blum, Leo Bonati, Giulio Conte, Michael Coslovsky, Maria Luisa De Perna, Marcello Di Valentino, Stefan Felder, Carola A Huber, Giorgio Moschovitis, Andreas Mueller, Rebecca E Paladini, Tobias Reichlin, Nicolas Rodondi, Annina Stauber, Christian Sticherling, Thomas D Szucs, David Conen, Michael Kuhne, Stefan Osswald, Matthias Schwenkglenks, Miquel Serra-Burriel
AIMS: Direct-acting oral anticoagulants (DOACs) have, to a substantial degree, replaced vitamin K antagonists (VKA) as treatments for stroke prevention in atrial fibrillation (AF) patients. However, evidence on the real-world causal effects of switching patients from VKA to DOAC is lacking. We aimed to assess the empirical incremental cost-effectiveness of switching patients to DOAC compared with maintaining VKA treatment. METHODS: The target trial approach was applied to the prospective observational Swiss-AF cohort, which enrolled 2415 AF patients from 2014 to 2017...
January 31, 2024: Open Heart